A Plasmodium falciparum candidate vaccine based on a six antigen polyprotein encoded by recombinant poxviruses
Background
All relevant background information can be found in the proposal submitted in response to a European Malaria Vaccine Initiative (EMVI), now European Vaccine Initiative call in 2002. The proposal was recommended by the independent Scientific Advisory Committee and subsequently approved by the Board in 2003.
Product Development
Product development took place as a result of a successful proposal submitted by the University of Oxford to the EMVI call 1998 under a contract signed in 2002 with the University of Oxford. The product development work was carried out by Impstofwerk Dessau-Tornau GmbH, Rosslau Germany, and Institute of Molecular Medicine John Radcliffe Hospital, University of Oxford.
Clinical Development
In 2004 two contracts were signed with the University of Oxford, both sponsored by EMVI for
a) a Phase I clinical trial:
A Phase I Study to Assess the Safety and Immunogenicity of the Polyprotein Malaria Vaccine Candidates Fp9 PP and MVA PP in Healthy Adults using a Prime Boost Delivery Schedule
and b) a Phase IIa non-randomised controlled challenge clinical trial:
Assessment of protection against malaria by sporozoite challenge of healthy adults vaccinated with the polyprotein malaria vaccines “FP9-PP,and MVA-PP” and control non-vaccinated volunteers.
